BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37964112)

  • 1. Safety of cinacalcet in children and adolescents with chronic kidney disease-mineral bone disorder: systematic review and proportional meta-analysis of case series.
    Zamoner SMS; Takase HM; Riyuzo MC; Caramori JCT; de Andrade LGM
    Int Urol Nephrol; 2024 May; 56(5):1669-1676. PubMed ID: 37964112
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparative Effectiveness of Calcimimetic Agents for Secondary Hyperparathyroidism in Adults: A Systematic Review and Network Meta-analysis.
    Palmer SC; Mavridis D; Johnson DW; Tonelli M; Ruospo M; Strippoli GFM
    Am J Kidney Dis; 2020 Sep; 76(3):321-330. PubMed ID: 32475604
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet in pediatric patients with chronic kidney disease and secondary hyperparathyroidism receiving dialysis.
    Warady BA; Iles JN; Ariceta G; Dehmel B; Hidalgo G; Jiang X; Laskin B; Shahinfar S; Vande Walle J; Schaefer F
    Pediatr Nephrol; 2019 Mar; 34(3):475-486. PubMed ID: 30506144
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cinacalcet studies in pediatric subjects with secondary hyperparathyroidism receiving dialysis.
    Warady BA; Ng E; Bloss L; Mo M; Schaefer F; Bacchetta J
    Pediatr Nephrol; 2020 Sep; 35(9):1679-1697. PubMed ID: 32367309
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of Cinacalcet and Etelcalcetide on Bone Mineral and Cardiovascular Disease in Dialysis Patients.
    Bernardor J; De Mul A; Bacchetta J; Schmitt CP
    Curr Osteoporos Rep; 2023 Apr; 21(2):193-204. PubMed ID: 36848027
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cinacalcet versus standard treatment for chronic kidney disease: a systematic review and meta-analysis.
    Sekercioglu N; Busse JW; Sekercioglu MF; Agarwal A; Shaikh S; Lopes LC; Mustafa RA; Guyatt GH; Thabane L
    Ren Fail; 2016 Jul; 38(6):857-74. PubMed ID: 27137817
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
    Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
    Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cinacalcet for Severe Secondary Hyperparathyroidism in Children with End-stage Kidney Disease.
    Sheerah AA; Al-Ahmed RA; El-Desoky SM; Alhasan KA; Albanna AS; Shalaby MA; Kari JA
    Saudi J Kidney Dis Transpl; 2021; 32(6):1628-1636. PubMed ID: 35946275
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The efficacy of cinacalcet combined with conventional therapy on bone and mineral metabolism in dialysis patients with secondary hyperparathyroidism: a meta-analysis.
    Li D; Shao L; Zhou H; Jiang W; Zhang W; Xu Y
    Endocrine; 2013 Feb; 43(1):68-77. PubMed ID: 22669774
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cinacalcet plus vitamin D versus vitamin D alone for the treatment of secondary hyperparathyroidism in patients undergoing dialysis: a meta-analysis of randomized controlled trials.
    Xu J; Yang Y; Ma L; Fu P; Peng H
    Int Urol Nephrol; 2019 Nov; 51(11):2027-2036. PubMed ID: 31531805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A Systematic Review and Meta-analysis of Efficacy and Safety of Calcimimetic Agents in the Treatment of Secondary Hyperparathyroidism in Patients with Chronic Kidney Disease.
    Liu Y; Yang Q; Chen G; Zhou T
    Curr Pharm Des; 2022; 28(40):3289-3304. PubMed ID: 36305135
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The impact of cinacalcet in the mineral metabolism markers of patients on dialysis with severe secondary hyperparathyroidism.
    Bucharles SGE; Barreto FC; Riella MC
    J Bras Nefrol; 2019 Jul; 41(3):336-344. PubMed ID: 31419274
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cinacalcet in pediatric and adolescent chronic kidney disease: a single-center experience.
    Alharthi AA; Kamal NM; Abukhatwah MW; Sherief LM
    Medicine (Baltimore); 2015 Jan; 94(2):e401. PubMed ID: 25590845
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cinacalcet use in paediatric dialysis: a position statement from the European Society for Paediatric Nephrology and the Chronic Kidney Disease-Mineral and Bone Disorders Working Group of the ERA-EDTA.
    Bacchetta J; Schmitt CP; Ariceta G; Bakkaloglu SA; Groothoff J; Wan M; Vervloet M; Shroff R; Haffner D;
    Nephrol Dial Transplant; 2020 Jan; 35(1):47-64. PubMed ID: 31641778
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cinacalcet as rescue therapy for refractory hyperparathyroidism in young children with advanced chronic kidney disease.
    Arenas Morales AJ; DeFreitas MJ; Katsoufis CP; Seeherunvong W; Chandar J; Zilleruelo G; Freundlich M; Abitbol CL
    Pediatr Nephrol; 2019 Jan; 34(1):129-135. PubMed ID: 30203374
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Incidence, predictors and therapeutic consequences of hypocalcemia in patients treated with cinacalcet in the EVOLVE trial.
    Floege J; Tsirtsonis K; Iles J; Drueke TB; Chertow GM; Parfrey P
    Kidney Int; 2018 Jun; 93(6):1475-1482. PubMed ID: 29525393
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients.
    Lee YT; Ng HY; Kuo CC; Chen TC; Wu CS; Chiu TT; Lee WC; Lee CT
    Nutrients; 2013 Apr; 5(4):1336-48. PubMed ID: 23603995
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cinacalcet HCl: a novel treatment for secondary hyperparathyroidism caused by chronic kidney disease.
    Torres PU
    J Ren Nutr; 2006 Jul; 16(3):253-8. PubMed ID: 16825031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cinacalcet: An oral calcimimetic agent for the management of hyperparathyroidism.
    Dong BJ
    Clin Ther; 2005 Nov; 27(11):1725-51. PubMed ID: 16368445
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Clinical and Practical Use of Calcimimetics in Dialysis Patients With Secondary Hyperparathyroidism.
    Bover J; Ureña P; Ruiz-García C; daSilva I; Lescano P; del Carpio J; Ballarín J; Cozzolino M
    Clin J Am Soc Nephrol; 2016 Jan; 11(1):161-74. PubMed ID: 26224878
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.